{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:28:04Z","timestamp":1777552084556,"version":"3.51.4"},"reference-count":68,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.jceh.2016.10.001","type":"journal-article","created":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T14:21:45Z","timestamp":1477059705000},"page":"311-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics"],"prefix":"10.1016","volume":"6","author":[{"given":"Amitkumar","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Seetharam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.jceh.2016.10.001_bib0345","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1056\/NEJM199611213352107","article-title":"Primary biliary cirrhosis","volume":"335","author":"Kaplan","year":"1996","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jceh.2016.10.001_bib0350","doi-asserted-by":"crossref","first-page":"926","DOI":"10.4254\/wjh.v7.i7.926","article-title":"Primary biliary cirrhosis: pathophysiology, clinical presentation and therapy","volume":"7","author":"Purohit","year":"2015","journal-title":"World J Hepatol"},{"issue":"5","key":"10.1016\/j.jceh.2016.10.001_bib0355","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J Hepatol"},{"issue":"10003","key":"10.1016\/j.jceh.2016.10.001_bib0360","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jceh.2016.10.001_bib0365","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1097\/MCG.0b013e3181f18c4e","article-title":"Varices in early histological stage primary biliary cirrhosis","volume":"45","author":"Ali","year":"2011","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"10.1016\/j.jceh.2016.10.001_bib0370","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/hep.510290603","article-title":"Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group","volume":"29","author":"Poupon","year":"1999","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jceh.2016.10.001_bib0375","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jceh.2016.10.001_bib0380","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jhep.2010.02.019","article-title":"Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis","volume":"53","author":"Corpechot","year":"2010","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jceh.2016.10.001_bib0385","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/hep.21076","article-title":"Increased prevalence of primary biliary cirrhosis near superfund toxic waste sites","volume":"43","author":"Ala","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jceh.2016.10.001_bib0390","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11908-012-0304-2","article-title":"Potential roles for infectious agents in the pathophysiology of primary biliary cirrhosis: what's new?","volume":"15","author":"Smyk","year":"2013","journal-title":"Curr Infect Dis Rep"},{"issue":"2","key":"10.1016\/j.jceh.2016.10.001_bib0395","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.gastro.2004.05.005","article-title":"Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment","volume":"127","author":"Selmi","year":"2004","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jceh.2016.10.001_bib0400","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.arcmed.2014.03.002","article-title":"HLA-DR polymorphism and primary biliary cirrhosis: evidence from a meta-analysis","volume":"45","author":"Li","year":"2014","journal-title":"Arch Med Res"},{"issue":"7","key":"10.1016\/j.jceh.2016.10.001_bib0405","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1440-1746.2012.07118.x","article-title":"Cytotoxic T-lymphocyte associated antigen-4 gene polymorphisms and primary biliary cirrhosis: a systematic review","volume":"27","author":"Li","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2016.10.001_bib0410","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathol-020712-164014","article-title":"The immunobiology and pathophysiology of primary biliary cirrhosis","volume":"8","author":"Hirschfield","year":"2013","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"10.1016\/j.jceh.2016.10.001_bib0415","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrgastro.2015.12","article-title":"Novel therapeutic targets in primary biliary cirrhosis","volume":"12","author":"Dyson","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jceh.2016.10.001_bib0420","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/hep.26979","article-title":"IL-12\/Th1 and IL-23\/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy","volume":"59","author":"Yang","year":"2014","journal-title":"Hepatology"},{"issue":"suppl 1","key":"10.1016\/j.jceh.2016.10.001_bib0425","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S2210-7401(12)70015-3","article-title":"Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action","volume":"36","author":"Poupon","year":"2012","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"10.1016\/j.jceh.2016.10.001_bib0430","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ajpath.2010.11.026","article-title":"Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis","volume":"178","author":"Allen","year":"2011","journal-title":"Am J Pathol"},{"issue":"4 Pt 1","key":"10.1016\/j.jceh.2016.10.001_bib0435","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/0016-5085(92)90778-W","article-title":"Cholestasis induces major histocompatibility complex class I expression in hepatocytes","volume":"102","author":"Calmus","year":"1992","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jceh.2016.10.001_bib0440","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bpg.2011.10.005","article-title":"Diagnosis of primary biliary cirrhosis","volume":"25","author":"Hirschfield","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.jceh.2016.10.001_bib0445","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jceh.2016.10.001_bib0450","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL Clinical Practice Guidelines: management of cholestatic liver diseases","volume":"51","author":"European Association for the Study of the L","year":"2009","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jceh.2016.10.001_bib0455","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0016-5085(93)90735-U","article-title":"Abnormal expression of anion exchanger genes in primary biliary cirrhosis","volume":"105","author":"Prieto","year":"1993","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jceh.2016.10.001_bib0460","first-page":"695","article-title":"Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells","volume":"118","author":"Arenas","year":"2008","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.jceh.2016.10.001_bib0465","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1006\/bbrc.1999.1403","article-title":"Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants","volume":"263","author":"Mitsuyoshi","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.jceh.2016.10.001_bib0470","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/gut.50.5.701","article-title":"Effect of ursodeoxycholic acid on methionine adenosyltransferase activity and hepatic glutathione metabolism in rats","volume":"50","author":"Rodriguez-Ortigosa","year":"2002","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.jceh.2016.10.001_bib0475","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/hep.510250505","article-title":"Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis","volume":"25","author":"Koga","year":"1997","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jceh.2016.10.001_bib0480","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hep.1840110104","article-title":"Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid","volume":"11","author":"Calmus","year":"1990","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jceh.2016.10.001_bib0485","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.4049\/jimmunol.156.4.1601","article-title":"Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway","volume":"156","author":"Tanaka","year":"1996","journal-title":"J Immunol"},{"issue":"8537","key":"10.1016\/j.jceh.2016.10.001_bib0490","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0140-6736(87)91610-2","article-title":"Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?","volume":"1","author":"Poupon","year":"1987","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jceh.2016.10.001_bib0495","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis","volume":"32","author":"Corpechot","year":"2000","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jceh.2016.10.001_bib0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making","volume":"10","author":"Dickson","year":"1989","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jceh.2016.10.001_bib0505","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2016.10.001_bib0510","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(11)60030-5","article-title":"An international study evaluating the farsenoid X receptor agonist obeticholic acid as monotherapy in PBC","volume":"54","author":"Kowdley","year":"2011","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jceh.2016.10.001_bib0515","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jceh.2016.10.001_bib0520","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1517\/14656566.2015.998650","article-title":"Advances in pharmacotherapy for primary biliary cirrhosis","volume":"16","author":"Mousa","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.jceh.2016.10.001_bib0525","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0022-2275(20)42003-6","article-title":"Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression","volume":"37","author":"Schoonjans","year":"1996","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.jceh.2016.10.001_bib0530","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.12290","article-title":"Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid","volume":"34","author":"Lens","year":"2014","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.jceh.2016.10.001_bib0535","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.hepres.2004.08.015","article-title":"Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate","volume":"30","author":"Matsumoto","year":"2004","journal-title":"Hepatol Res"},{"issue":"2","key":"10.1016\/j.jceh.2016.10.001_bib0540","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jceh.2016.10.001_bib0545","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3748\/wjg.v10.i6.894","article-title":"Fenofibrate for patients with asymptomatic primary biliary cirrhosis","volume":"10","author":"Dohmen","year":"2004","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jceh.2016.10.001_bib0550","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MCG.0b013e3181c115b3","article-title":"Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid","volume":"44","author":"Hazzan","year":"2010","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"10.1016\/j.jceh.2016.10.001_bib0555","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1440-1746.2011.06737.x","article-title":"Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid","volume":"26","author":"Takeuchi","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jceh.2016.10.001_bib0560","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1751-2980.2012.00574.x","article-title":"Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy","volume":"13","author":"Han","year":"2012","journal-title":"J Dig Dis"},{"issue":"3","key":"10.1016\/j.jceh.2016.10.001_bib0565","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MOG.0000000000000056","article-title":"Fibrate treatment for primary biliary cirrhosis","volume":"30","author":"Cuperus","year":"2014","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jceh.2016.10.001_bib0570","first-page":"2757","article-title":"Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.1016\/j.jceh.2016.10.001_bib0575","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ajg.2015.20","article-title":"A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia","volume":"110","author":"Hosonuma","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jceh.2016.10.001_bib0580","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.jceh.2016.10.001_bib0585","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1572-0241.2002.05944.x","article-title":"Fenofibrate treatment in patients with primary biliary cirrhosis","volume":"97","author":"Ohira","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jceh.2016.10.001_bib0590","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1055\/s-0034-1383733","article-title":"Old and novel therapies for primary biliary cirrhosis","volume":"34","author":"Pares","year":"2014","journal-title":"Semin Liver Dis"},{"issue":"4","key":"10.1016\/j.jceh.2016.10.001_bib0595","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jceh.2016.10.001_bib0600","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jceh.2016.10.001_bib0605","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid","volume":"31","author":"Angulo","year":"2000","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jceh.2016.10.001_bib0610","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jceh.2016.10.001_bib0615","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/hep.27313","article-title":"Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis","volume":"60","author":"Zhang","year":"2014","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jceh.2016.10.001_bib0620","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ajg.2013.51","article-title":"B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid","volume":"108","author":"Myers","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2016.10.001_bib0625","first-page":"1","article-title":"Proposed therapies in primary biliary cholangitis","author":"Floreani","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.jceh.2016.10.001_bib0630","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.cgh.2007.07.015","article-title":"Transplantation trends in primary biliary cirrhosis","volume":"5","author":"Lee","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jceh.2016.10.001_bib0635","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/jhep.2001.20894","article-title":"Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center","volume":"33","author":"Liermann Garcia","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2016.10.001_bib0640","first-page":"176A","article-title":"Transplantation for primary biliary cirrhosis: Recurrence and outcome in 421 patients (abstract)","volume":"26","author":"Abu-Elamgd","year":"1997","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jceh.2016.10.001_bib0645","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/lt.20123","article-title":"Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation","volume":"10","author":"Neuberger","year":"2004","journal-title":"Liver Transpl"},{"issue":"6","key":"10.1016\/j.jceh.2016.10.001_bib0650","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jhep.2015.07.038","article-title":"Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence","volume":"63","author":"Bosch","year":"2015","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jceh.2016.10.001_bib0655","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jceh.2016.10.001_bib0660","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"issue":"3","key":"10.1016\/j.jceh.2016.10.001_bib0665","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jceh.2016.10.001_bib0670","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jceh.2016.10.001_bib0675","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.jceh.2016.10.001_bib0680","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688316303024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688316303024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:03:51Z","timestamp":1760853831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688316303024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0973688316303024"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2016.10.001","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2016.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 INASL.","name":"copyright","label":"Copyright"}]}}